The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Cases of a bacterial infection called "rabbit fever" have been increasing during the past decade, according to the U.S.

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...